SPYRE THERAPEUTICS, INC. Asset Acquisition Consideration Transferred Transaction Cost
SPYRE THERAPEUTICS, INC. (SYRE) had Asset Acquisition Consideration Transferred Transaction Cost of $3.20 million as of 2023-06-22, per its 10-Q filed 2023-08-11.
Discontinued › Notes › Asset Acquisition, Consideration Transferred
us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost · last filed 2023-08-11
- 2023-06-22: Asset Acquisition Consideration Transferred Transaction Cost $3.20M.
| Period end | Asset Acquisition Consideration Transferred Transaction Cost |
|---|---|
| 2023-06-22 | $3.20M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |